about
Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individualsHeteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophreniaCalcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growthA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesHistamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspectiveHomozygous Deletion of Glutathione Peroxidase 1 and Aldehyde Dehydrogenase 1a1 Genes Is Not Associated with Schizophrenia-Like Behavior in MicePopulation-based input function modeling for [(18)F]FMPEP-d 2, an inverse agonist radioligand for cannabinoid CB1 receptors: validation in clinical studiesSerotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendationsAntipsychotic-like effects of a neurotensin receptor type 1 agonist.G protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionDopaminergic contributions to hippocampal pathophysiology in schizophrenia: a computational studyModeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.Effect of maternal lipopolysaccharide administration on the development of dopaminergic receptors and transporter in the rat offspring.Reward processing in autism: a thematic series.N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.Dopaminergic dysfunction in schizophrenia: salience attribution revisited.Beyond dopamine: functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis.Interneuron precursor transplants in adult hippocampus reverse psychosis-relevant features in a mouse model of hippocampal disinhibition.Further evidence for aberrant prefrontal salience coding in schizophrenia.Dopamine D₂ and acetylcholine α7 nicotinic receptors have subcellular distributions favoring mediation of convergent signaling in the mouse ventral tegmental area.Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depressionNeurobiology of aggression and violence in schizophrenia.AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.From reinforcement learning models to psychiatric and neurological disorders.Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia.Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.Presynaptic regulation of dopamine transmission in schizophrenia.Reinforcement learning deficits in people with schizophrenia persist after extended trials.The role of dopamine for the pathophysiology of schizophrenia.Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients.Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Transient inactivation of the neonatal ventral hippocampus permanently disrupts the mesolimbic regulation of prefrontal cholinergic transmission: implications for schizophreniaRisperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.Cannabinoid modulation of functional connectivity within regions processing attentional salience.
P2860
Q21136367-69B32FAA-3FF2-4989-AB3D-0C767BB9BC7CQ24630645-79DEFDF0-F696-43E2-8451-6836FC3FD74CQ24632939-EE9DE3DF-61AF-4009-BF58-E832C81C786CQ24656080-BED659FD-84EE-4C39-8809-F5CA3913E9FAQ26786354-1274B5DF-BBFC-4296-B110-9681A2FA2B11Q28073102-D5346067-AE71-4AF5-A206-F90920A0840EQ28395280-3BDB0788-7823-4A72-B00E-1BB6FFB8B400Q28486023-5428D58E-288F-4AE8-958F-95575BFDDF0CQ28731687-6E4C7BAE-1891-42AC-A733-2DC3156F8FA1Q30356261-FBCBEA51-26ED-4DAC-82DF-293EB3FFC300Q30385233-29328623-825C-4C72-803C-F54262D4AA6FQ30386608-44B6820B-8A3F-4186-BC41-C85B19D3FD3CQ30410514-4D374A5A-BCD2-4BD5-820C-3ACC9B4C28C1Q30454958-E9AEAC01-9207-4878-8CAE-B8F5E9138FB6Q30458391-16129F9B-1A22-41DC-BF5E-041F30D8A331Q30458917-F9A7C0F8-0815-44B8-A940-1878F4C3AF51Q30462673-2026A4F1-88F8-415E-94AE-1877DEBEC69AQ30474021-F3E500BF-7193-4464-AED1-911B4F10E8F9Q30474409-27DE3A62-D170-4063-9D02-97308A4CFD38Q30475711-8743463A-A398-45F1-A538-834852E1FBEAQ30483150-17D65E94-6A3F-4595-A46B-83AEFB35E1A3Q30578889-A1FAED86-D173-40B8-9234-5B22FACB4F7DQ33650034-B11CA9FF-49FE-4EDB-9280-3CB23DBA2D2BQ33751420-AEA4065A-1E00-4B9A-8D3E-B5D38FD694A3Q33798728-AD5A6791-285D-4A74-91F5-EADAEBEA1D9FQ34000699-C8878A7D-588F-424D-B02D-DC31485D3732Q34076241-08AD1460-DE2A-4A66-A2F3-15BAD752CCB2Q34161002-5BAA0591-90E2-4022-89D7-D76CD6A4A06EQ34250017-E1FDCD18-CFB7-476B-846F-1790E22A83F0Q34264520-2C68923C-702D-4FF9-8326-918F0F6D8D7EQ34350145-43359071-D341-4E97-9AD1-EF9EF2E04466Q34415890-FE5C4A2F-3DEE-4646-893A-45D4D59027F8Q34644139-C69EDC15-D089-4E4B-AAB5-C6D0A5DB3C09Q34658860-4FF5EBC3-3E4C-4E39-9F13-AAB79DAE0313Q34703195-B3454108-5053-418F-B55F-862ED862E485Q34948226-0F842B0F-1B8E-4AC9-A151-B5CBF1B0EC85Q35071909-984CDD13-3D90-48FB-BBE3-303D555CC56FQ35356707-91DB92CC-B4D3-40AE-9201-190ACEE398C7Q35390344-70278C6F-3747-49C5-A585-A390B2C7A452Q35420974-E1043315-DB58-441B-9363-950742AE713E
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Neurobiology of dopamine in schizophrenia.
@ast
Neurobiology of dopamine in schizophrenia.
@en
type
label
Neurobiology of dopamine in schizophrenia.
@ast
Neurobiology of dopamine in schizophrenia.
@en
prefLabel
Neurobiology of dopamine in schizophrenia.
@ast
Neurobiology of dopamine in schizophrenia.
@en
P1476
Neurobiology of dopamine in schizophrenia.
@en
P2093
Marc Laruelle
Olivier Guillin
P356
10.1016/S0074-7742(06)78001-1
P577
2007-01-01T00:00:00Z